EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Comprehensive Review on the Advancements of Dual COX ‐2/5‐ LOX Inhibitors as Anti‐Inflammatory Drugs

Neetu Agrawal iD

Chemical Biology & Drug Design · 2025-05 · 105 (5)

DOI: 10.1111/cbdd.70114 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 10.05.2025. Verfasst von Neetu Agrawal. Beteiligte Einrichtung: Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Cyclooxygenase 2 Inhibitors, Lipoxygenase Inhibitors, Cyclooxygenase 2, Arachidonate 5-Lipoxygenase. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic pain and inflammation are widespread clinical issues that significantly affect patients' quality of life and are often associated with serious conditions such as arthritis, cancer, and cardiovascular disease. Effective management of inflammation is therefore a major public health priority. Current anti‐inflammatory treatments—including non‐steroidal anti‐inflammatory drugs (NSAIDs), corticosteroids, disease‐modifying antirheumatic drugs (DMARDs), and biologics—offer symptomatic relief but are frequently limited by side effects such as gastrointestinal toxicity, immunosuppression, or cardiovascular risks. Moreover, most of these therapies target only a single pathway in the inflammatory cascade. Dual inhibitors of COX‐2 and 5‐LOX have emerged as a promising therapeutic class, as they simultaneously block two key enzymes involved in prostaglandin and leukotriene synthesis. This dual‐action approach offers enhanced efficacy and may reduce adverse effects linked to selective or non‐selective COX inhibition. This review discusses the underlying mechanisms of inflammation, evaluates current treatment options, and highlights the pharmacological advantages and development status of dual COX‐2/5‐LOX inhibitors as a next‐generation strategy for inflammation management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclooxygenase 2 InhibitorsLipoxygenase InhibitorsCyclooxygenase 2Arachidonate 5-LipoxygenaseAnti-Inflammatory Agents, Non-SteroidalAnti-Inflammatory AgentsHumansInflammationAnimals

Stichwörter der Autor:innen

anti‐inflammatorycyclooxygenasedual COX‐2/LOX‐5inflammationlipoxygenase

Substanzen

Cyclooxygenase 2 InhibitorsLipoxygenase InhibitorsCyclooxygenase 2Arachidonate 5-LipoxygenaseAnti-Inflammatory Agents, Non-SteroidalAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.

ORCID-Profile: Neetu Agrawal

Zitieren

APA

Agrawal, N. (2025). A Comprehensive Review on the Advancements of Dual COX ‐2/5‐ LOX Inhibitors as Anti‐Inflammatory Drugs. Chemical Biology & Drug Design, 105(5). https://doi.org/10.1111/cbdd.70114

Vancouver

Agrawal N. A Comprehensive Review on the Advancements of Dual COX ‐2/5‐ LOX Inhibitors as Anti‐Inflammatory Drugs. Chemical Biology & Drug Design. 2025;105(5). doi:10.1111/cbdd.70114

BibTeX
@article{Agrawal2025,
  author = {Agrawal, Neetu},
  title = {A Comprehensive Review on the Advancements of Dual COX ‐2/5‐ LOX Inhibitors as Anti‐Inflammatory Drugs},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  volume = {105},
  number = {5},
  doi = {10.1111/cbdd.70114}
}
Kostenlos starten →